Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
Sign Up to like & getrecommendations! Published in 2019 at "Oncoimmunology"
DOI: 10.1080/2162402x.2019.1615817
Abstract: ABSTRACT Pexastimogene devacirepvec (Pexa-Vec) is a vaccinia virus-based oncolytic immunotherapy designed to preferentially replicate in and destroy tumor cells while stimulating anti-tumor immunity by expressing GM-CSF. An earlier randomized Phase IIa trial in predominantly sorafenib-naïve… read more here.
Keywords: pexa vec; trial; pexastimogene devacirepvec; vec ... See more keywords